New cancer drug enters first human trials
NCT ID NCT07486700
Summary
This is the first study testing a new cancer drug called SIG001 in people. Researchers want to find the safest dose for patients with advanced solid tumors that haven't responded to standard treatments. The study will enroll 66 patients who will receive the drug through an IV every two weeks while doctors monitor their safety and how their bodies handle the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLAMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.